WELL LEAD MEDICAL CO LTD Class A

WELL LEAD MEDICAL CO LTD Class A

SSSE:603309
10.95
CNY
+0.02
(+0.18%)
0.16EPS
98.33P/E
3.26BMarket Cap
Apr 16Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
2.25
2.53
2.22
2
2.4
2.89
3.86
4.36
4.32
4.67
4.76
5.16
5.56
5.71
Basic EPS, GAAP
0.33
0.35
0.37
0.31
0.25
0.25
0.47
0.59
0.41
0.57
0.66
0.75
0.26
0.11
Free Cash Flow per Basic Share
0.15
0.29
0.18
0.06
0.01
0.04
0.26
0.52
0.3
0.72
-0.46
-0.03
0.42
- -
Dividend per Share
0.02
0.07
0.12
- -
0.11
0.13
0.13
0.19
0.23
0.16
0.37
0.53
0.54
0.54
Book Value per Share
1.55
1.9
2.99
3.3
3.43
3.56
3.95
4.36
5.98
5.88
6.2
6.44
6.04
6.26
Tangible Book Value per Share
1.27
1.63
2.78
3.08
3.22
1.93
2.26
2.64
4.18
4.29
4.63
4.82
4.95
5.2
Basic Weighted Avg Shares
194
196
247
258
262
258
258
260
259
292
292
293
294
290
Sales/Revenue/Turnover
437
496
549
515
630
746
994
1,131
1,119
1,363
1,388
1,509
1,631
1,658
Operating Margin (%)
18.73
18.46
14.44
13.37
11.97
8.99
16.26
20.44
14.38
15.81
17.79
17.84
18.67
16.49
Depreciation Expense
12
15
17
19
22
29
43
49
58
66
73
74
91
- -
Net Income, GAAP
64
68
91
79
65
65
121
153
106
167
192
219
76
33
Effective Tax Rate (%)
18.54
22.15
9.22
17.38
17.14
17.72
15.73
15.9
18.22
13.57
13.78
13.14
33.12
45.02
Profit Margin (%)
14.54
13.66
16.64
15.38
10.25
8.77
12.19
13.54
9.48
12.22
13.87
14.54
4.68
1.99
Working Capital
63
98
489
505
474
132
189
194
548
517
376
354
330
417
LT Debt
- -
- -
- -
- -
- -
201
167
123
92
137
287
357
396
381
Total Equity
302
370
779
863
900
939
1,036
1,144
1,591
1,740
1,837
1,903
1,777
1,842
Return on Invested Capital (%)
17.68
16.71
14.52
8.46
6.73
5.42
9.96
12.79
7.35
9.23
9.64
9.91
3.63
- -
Return on Capital (%)
18.76
18.03
15.39
9.72
8.54
7.34
10.51
12.01
6.62
8.47
8.91
9.58
3.26
- -
Return on Common Equity (%)
23.09
20.2
15.91
9.69
7.38
7.19
12.4
14.17
7.82
10.09
10.87
11.85
4.19
- -

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
220
207
218
LT Borrowings
332
344
336
LT Finance Leases
54
46
45
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
292
292
292
Market Capitalization
4,352
3,275
3,263

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
869
856
951
Cash, Cash Equivalents & STI
460
435
494
Accounts Receivable, Net
178
192
203
Inventories
187
199
221
Total Current Liabilities
475
494
534
Payables & Accruals
- -
- -
- -
ST Debt
220
207
218
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
9.12%
10.19%
-6.65%
Free Cash Flow
-84.18%
-308.36%
-1,410.55%
Net Income, GAAP
7.18%
-1.88%
-65.21%
Sales/Revenue/Turnover
12.1%
7.89%
8.07%
Total Cash Common Dividend
- -
35.25%
2.31%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
309
367
384
449
1,509
2025
348
397
- -
440
1,631
2026
357
412
449
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.17
0.19
0.21
0.18
0.75
2025
0.2
0.21
- -
-0.4
0.26
2026
0.21
0.14
0.16
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.01
0.43
0.1
-0.02
0.53
2025
0.01
0.51
- -
0.01
0.54
2026
0.22
0.31
0.01
- -
- -

Company Description

CEO
Guang Yuan Han
Full Time Employees
2,849
Sector
Health technology
Industry
Medical specialties
Address
47, Guomao Avenue South Guangzhou GD China 511434
IPO Date
Feb 9, 2015
Business
Well Lead Medical Co., Ltd. (603309.SS) develops, manufactures and sells medical catheters and devices focused on urology, endourology, anaesthesia, respiratory, pain management, hemodialysis and home care segments. The company offers urology products including Foley catheters, Nelaton catheters, urine collection products and accessories; endourology products such as the ClearPetra family system, ureterorenoscopes, guide wires, ureteral stents and stone retrieval baskets; anaesthesia products comprising endotracheal tubes, intubation accessories, laryngeal masks, endobronchial tubes, tracheostomy tubes, anaesthesia breathing circuits and accessories, nasopharyngeal and oropharyngeal airway products; respiratory products including oxygen and aerosol therapy products, capnography masks and cannula products; drainage, suction and gastroenterology products such as drainage systems, Yankauer handles, suction catheters, stomach and feeding tubes; hemodialysis blood tubing sets; home care products including male external catheters and Convicath intermittent catheters; and ambulatory infusion pumps for pain management. Well Lead Medical serves hospitals, therapy clinics, emergency and clinical care facilities worldwide, with products sold in more than 96 countries and regions including North America, Europe, Japan, Canada, Australia and Brazil, and utilized in over 700 Grade III Level A hospitals in China. Founded in 1998 and headquartered in Panyu District, Guangzhou, China, the company maintains subsidiaries such as Hainan Well Lead Medical Technology Development Co., Ltd. and operates production facilities including a new base in Mexico slated for operation in early 2026. Recent developments include a 2024 exclusive distribution agreement with KARL STORZ United States for the ClearPetra Stone management system, ongoing export growth to Europe, South America and Southeast Asia amid US market stability at around 15% of revenue, and establishment of a production base in Mexico to support localized overseas operations.